胺甲斑蝥素对GABAC受体的影响

doi:10.5246/jcps.2012.03.032

胺甲斑蝥素对GABAC受体的影响

张艳欣, 廖玉芳, 王明正^*, 古艳婷, 肖奕, 王新风

山西医科大学药理教研室, 山西太原 030001

收稿日期:2011-12-27 修回日期:2012-03-10 出版日期:2012-05-15 发布日期:2012-05-15
通讯作者: 王明正*

Effects of 4-amino-2-methyl-cantharidinimide on GABAC receptors

Yan-Xin Zhang, Yu-Fang Liao, Ming-Zheng Wang^*, Yan-Ting Gu, Yi Xiao, Xin-Feng Wang

Department of Pharmacology, Shanxi Medical University, Taiyuan 030001, China

Received:2011-12-27 Revised:2012-03-10 Online:2012-05-15 Published:2012-05-15
Contact: Ming-Zheng Wang*

摘要/Abstract

摘要： 已有胺甲斑蝥素的抗惊厥作用的相关报道, 但其作用机制不明, 本实验研究了胺甲斑蝥素对GABAC受体的影响。采用青霉素诱发的大鼠癫痫模型, 在注射青霉素前30分钟, 对应不同分组分别给予灌胃胺甲斑蝥素88 mg/kg、22 mg/kg, 丙戊酸钠154 mg/kg。应用脑电图监测大鼠痫样活动时脑电波的变化, 免疫组织化学技术测定GABA和GABAC受体在海马区的水平, 实时监测的聚合酶链式反应技术测定GABAC受体亚基ρ2的mRNA表达水平。与对照组相比, 胺甲斑蝥素组和丙戊酸钠组的痫样活动振幅和频率都明显降低, GABA和GABAC受体在海马区的水平以及GABAC受体亚基ρ2的mRNA表达水平明显增加。实验表明胺甲斑蝥素和丙戊酸钠都可抑制癫痫发作, 我们认为氨甲斑蝥素的抗惊厥作用的机制可能是通过调节GABA和GABAC受体水平来实现的。

关键词: 胺甲斑蝥素, 抗惊厥作用, GABAC受体, 免疫组织化学, 实时荧光定量聚合酶链反应

Abstract:

The antiepileptic effect of 4-amino-2-methyl-cantharidinimide (AMC) was reported, but its mechanism remains unknown. In this study, we investigated the effects of AMC on a rat model of penicillin-induced epilepsy. The doses of 88 and 22 mg/kg AMC and the dose of 154 mg/kg sodium valproate (VPA) were administered intragastrically (i.g.) 30 min before penicillin injection, respectively. The epileptiform activity was verified by electrocorticographic (ECoG) recordings. The levels of GABA and GABAC receptors in hippocampus were determined by immunohistochemistry, and real-time polymerase chain reaction (RT-PCR) technique was used to detect the mRNA expression of GABAC receptor ρ2. The mean frequency and amplification of spike epileptiform activity were significantly decreased in AMC and VPA-pretreated rats compared with those of non-pretreated penicillin-induced epilepsy (PIE) group. The levels of GABA, GABAC receptors and the mRNA expression of GABAC receptors ρ2 in AMC and VPA-pretreated rats were significantly increased as compared with PIE group. These findings indicate that AMC and VPA have an antiepileptic effect on PIE in rats, and the antiepileptic effect of AMC may be mediated by the GABAC receptors and GABA.

Key words: 4-Amino-2-methyl-cantharidinimide, Antiepileptic effect, GABAC receptors, Immunohistochemistry, RT-PCR

中图分类号:

R962.2

Supporting:

Foundation item: Scientific and Technological Innovation Foundation of Shanxi Medical University (Grant No. 01200804).
*Corresponding author. Tel.: 86-351-4962091; 13934649769

张艳欣, 廖玉芳, 王明正^*, 古艳婷, 肖奕, 王新风. 胺甲斑蝥素对GABAC受体的影响[J]. , DOI: 10.5246/jcps.2012.03.032.

Yan-Xin Zhang, Yu-Fang Liao, Ming-Zheng Wang^*, Yan-Ting Gu, Yi Xiao, Xin-Feng Wang . Effects of 4-amino-2-methyl-cantharidinimide on GABAC receptors [J]. , DOI: 10.5246/jcps.2012.03.032.

参考文献

[1] Nakayama, Y.; Hattori, N.; Otani, H.; Inagaki, C. Biochem. Pharm. 2006, 71, 1705-1710.
[2] López-Chávez, A.; Miledi, R.; Martínez-Torres, A. J. Neurosci. Res. 2005, 53, 421-427.
[3] Chebib, M.; Hanrahan, J.R.; Kumar, R.J.; Mewett, K.N.; Morriss, G.; Wooller, S.; Johnston, G.A. Neuropharmacology. 2007, 52, 779-787.
[4] Schlicker, K.; Boller, M.; Schmidt, M. Brain Res. Bull. 2004, 63, 91-97.
[5] Johnston, G.A.; Chebib, M.; Hanrahan, J.R.; Mewett, K.N. Curr. Drug Targets CNS Neurol. Disord. 2003, 2, 260-268.
[6] Li, C.D. J. Tradit. Chin. Med. Sichuan. 1993, 11, 17-20.
[7] Chen, X.L.; Zhang, Q.Q.; Wang, M.Z.; Xiao, Y.; Liao, Y.F.; Wang, X.F. Chin. J. Integr. Medicine on Cardio-/Cerebrovascular Disease. 2009, 9, 83-85.
[8] Li, Y.X.; Sun, X.F.; Wei, C.Q. Central South Pharm. 2008, 6, 542-549.
[9] Joshi, B.S.; David, J.; Gawad, D.H. Indian J. Chem. 1983, 22, 131-135.
[10] Vamecq, J.; Bac, P.; Herrenknecht, C.; Maurois, P.; Delcourt, P.; Stables, J.P. J. Med. Chem. 2000, 43, 1311-1319.
[11] Xiao, Y.; Gu, Y.T.; Wang, M.Z.; Wang, X.F.; Liao, Y.F.; Zhang, Y.X. J. Chin. Pharm. 2011, 46, 16-22.
[12] Kozan, R.; Sefil, F.; Bağirici, F. J. Brain Res. 2008, 1239, 249-255.
[13] Macdonald, R.L.; Gallagher, M.J.; Feng, H.J.; Kang, J.Q. Biochem. Pharm. 2004, 68, 1497-1506.
[14] Richard, R.; Kerstin, M.L.M. Neurocomputing. 2007, 70, 1619-1625.
[15] Yu, J.L.; Chen, Z.X.; Mao, X.Y.; Meng, X.J.; Guo, F.; Liu, R.; Wu, K.Z. Chin. Pharm. Bull. 2009, 25, 1530-1533.
[16] Yang, B.; Wang, B.F.; Lai, M.J. Acta Pharm. Sin. 2011, 10, 1-6.
[17] Ramsey, D.J.; Ripps, H.; Qian, H. Exp. Eye Res. 2007, 85, 413-422.
[18] Nie, H.G.; Cai, J.Q.; Yao, W.F. Chin. Pharm. Bull. 2007, 23, 597-600.
[19] Tao, Y.H.; Jiang, D.Y.; Xu, H.B.; Yang, X.L. Phyto-medicine. 2008, 15, 92-97.
[20] Ren, L.H.; Wang, F.; Xu, Z.W.; Chan, W.M.; Zhao, C.Y.; Xue, H. Biochem. Pharma. 2010, 79, 1337-1344.
[21] McGillem, G.S.; Rotolo, T.C.; Dacheux, R.F. Vis. Neurosci. 2000, 17, 381-389.
[22] Rozzo, A.; Armellin, M.; Franzot, J.; Chiaruttini, C.; Nistri, A.; Tongiorgi, E. Eur. J. Neurosci. 2002, 15, 1747-1758.
[23] Johnston, G.A.; Chebib, M.; Hanrahan, J.R.; Mewett, K.N. Neurochem. Res. 2010, 35, 1970-1977.
[24] Gibbs, M.E.; Johnston, G.A. Neuroscience. 2005, 131, 567-576.
[25] Lee, Y.; Kim, D.; Kim, Y.H.; Lee, H.; Lee, C.J. Eur. J. Pharmacol. 2010, 643, 225-231.